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Abstract
Rationale: Excessive daytime sleepiness is a common disabling
symptom in obstructive sleep apnea syndrome.
Objectives: To evaluate the efficacy and safety of pitolisant, a
selective histamine H3 receptor antagonist with wake-promoting
effects, for the treatment of daytime sleepiness in patients with
moderate to severe obstructive sleep apnea refusing continuous
positive airway pressure treatment.
Methods: In an international, multicenter, double-blind,
randomized (3:1), placebo-controlled, parallel-design trial, pitolisant
was individually titrated at up to 20mg/d over 12weeks. The primary
endpoint was the change in the Epworth Sleepiness Scale score. Key
secondary endpoints were maintenance of wakefulness assessed on
the basis of the Oxford Sleep Resistance test, safety, Clinical Global
Impression of severity, patient’s global opinion, EuroQol quality-of-
life questionnaire, and Pichot fatigue questionnaire.
Measurements and Main Results: A total of 268 patients with
obstructive sleep apnea (75%male;mean age, 52 yr; apnea–hypopnea
index, 49/h; baseline sleepiness score, 15.7) were randomized (200
to pitolisant and 68 to placebo) and analyzed on an intention-to-
treat basis. The Epworth Sleepiness Scale score was reduced
more with pitolisant than with placebo (22.8; 95% confidence
interval,24.0 to21.5; P, 0.001). Wake maintenance tests were
not improved. The Pichot fatigue score was reduced with
pitolisant. The overall impact of pitolisant was confirmed by
both physicians’ and patients’ questionnaires. Adverse event
incidence, mainly headache, insomnia, nausea, and vertigo, was
similar in the pitolisant and placebo groups (29.5% and 25.4%,
respectively), with no cardiovascular or other significant safety
concerns.
Conclusions: Pitolisant significantly reduced self-reported daytime
sleepiness and fatigue and improved patient-reported outcomes
and physician disease severity assessment in sleepy patients with
obstructive sleep apnea refusing or nonadherent to continuous
positive airway pressure.
Clinical trial registered with www.clinicaltrials.gov (NCT01072968)
and EU Clinical Trials Register (EudraCT 2009-017251-94).
Keywords: excessive daytime sleepiness; obstructive sleep apnea;
continuous positive airway pressure; pitolisant
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Obstructive sleep apnea (OSA) is a major
health concern worldwide that has
multiorgan consequences and results in
considerable economic, healthcare, and
social burdens (1, 2). OSA is often
associated with comorbidities such as
arterial hypertension, arrhythmia, stroke,
coronary heart disease, and metabolic
dysfunction. Excessive daytime sleepiness
(EDS) and fatigue are among the chief
complaints of patients with OSA, and they
have disabling consequences: impaired
attention and vigilance, cognitive
dysfunction, loss of productivity at work,
deterioration in quality of life, and
increased risk of occupational and motor
vehicle accidents (3, 4).
Continuous positive airway pressure
(CPAP) is the first-line therapy for
symptomatic moderate to severe OSA.
When used properly, CPAP normalizes the
apnea–hypopnea index (AHI), suppresses
nocturnal oxygen desaturations, and
decreases sleep fragmentation. As a
consequence, there is a general reduction
in EDS, and improvements in alertness,
cognitive function, and quality of life are
seen. CPAP is particularly effective in
patients with more pronounced sleepiness
and OSA severity (5, 6). However,
sleepiness is known to persist in
approximately 15% of patients in spite of
adequate CPAP therapy, and this residual
component may represent a considerable
therapeutic drawback (7–9). Wake-
promoting agents such as modafinil and
armodafinil, as well as, more recently,
solriamfetol, in combination with CPAP
have been demonstrated to decrease residual
sleepiness and improve quality of life in
randomized controlled trials (10, 11).
A major issue with CPAP treatment
is adherence, with 15% of patients with
OSA refusing to try CPAP and 20–30%
discontinuing CPAP in the long term (12,
13). Hence, prescribing a wake-promoting
agent to selectively treat EDS and not
treating the underlying cause is frequently
debated, and efficacy data are scarce in this
specific context.
Pitolisant is a novel selective histamine
H3 receptor antagonist/inverse agonist with
strong wake-promoting effects that is well
tolerated in patients with narcolepsy (14,
15). This provides a rationale to assess its
efficacy and safety in the treatment of EDS
in patients with OSA who refuse or do not
adhere to CPAP therapy. The objectives of
this study were to demonstrate the efficacy
and safety of pitolisant administered at 5,
10, or 20 mg once per day versus placebo
during 12 weeks for the treatment of EDS
in patients with moderate to severe OSA
and refusing CPAP therapy.
Methods
Study Design
This phase 3, prospective, double-blind,
placebo-controlled, parallel-group,
multicenter study evaluated the efficacy and
safety of pitolisant over 12 weeks in adult
patients with moderate to severe OSA (AHI,
>15 events/h) experiencing EDS (Epworth
Sleepiness Scale [ESS] score, >12), refusing
CPAP treatment, and without significant
cardiovascular disease. The study was
conducted in 28 hospital sleep clinics in
10 European countries between October 6,
2011, and May 7, 2014. The study was
approved by the appropriate institutional
review board or ethics committee of each
study center and was performed in
accordance with the principles of the
Declaration of Helsinki. All patients
provided written informed consent before
participation. The study is registered with
www.clinicaltrials.gov (NCT01072968) and
the EU Clinical Trials Register (EudraCT
2009-017251-94).
Patients
Patients were adults with OSA diagnosed
according to the International Classification
of Sleep Disorders 2nd Edition (16) criteria
and refusing or not adhering to CPAP
therapy. Included patients with OSA were
those with an AHI >15 events per hour
assessed during the previous year and a
complaint of EDS, defined as an ESS score
>12.
Key noninclusion criteria were as follows:
d History of a medical disorder other than
OSA associated with EDS (periodic limb
movement arousal index, .10 events/h;
13-item Beck Depression Inventory
[BDI-13] score, .16 or item G= 0; Mini
Mental State Examination score, 28)
d Body mass index (BMI) .40 kg/m2
(owing to the risk of obesity
hypoventilation syndrome and because
morbid obesity might be a significant
cause of sleepiness)
d Surgery for OSA, including
uvulopalatopharyngoplasty
d Use of a mandibular advancement device
d Nighttime or variable work shifts
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At a Glance Commentary
Scientific Knowledge on the
Subject: Some patients with
obstructive sleep apnea who refuse or
do not adhere to continuous positive
airway pressure treatment have
persistent daytime sleepiness.
What This Study Adds to the Field:
In this randomized placebo-controlled
trial, pitolisant, a selective histamine
H3 receptor antagonist with wake-
promoting effects, significantly
reduced sleepiness and fatigue and
improved both global patient-reported
outcomes and the physician’s disease
severity assessment. Importantly, no
detrimental cardiovascular impact was
associated with this therapy.
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d Current or recent history of drug,
alcohol, or other substance abuse or
dependence
d Presence of an unstable or clinically
significant medical condition
d A behavior or psychiatric disorder or
medical history that could affect safety or
interfere with study assessments
d Use of any treatment that could affect
the evaluation of EDS
Cardiovascular disease, including
myocardial infarction, hypertension, angina,
arterial hypertension or dysrhythmia,
electrocardiogram, Bazett’s corrected QT
interval longer than 450 ms on an ECG, left
ventricular hypertrophy, or mitral valve
prolapse, was not exclusionary, unless the
investigator deemed it unstable or recent.
Randomization Procedure
Randomization was centralized and
performed via an electronic web
randomization server (Arone Projection;
https://www.bioprojet-studies.org/) that
automatically assigned a patient number at
screening and then automatically assigned a
study treatment number when the patient
was randomized. The randomization list
was established on a balanced 3:1 (three
active for one placebo) basis. Pitolisant and
placebo were contained within sealed
capsules, similar in appearance and taste,
and containing a one-fourth, one-half, or
one full tablet of pitolisant 20 mg or lactose
only (placebo). The patients, their sleep
and/or respiratory physicians, and staff
were blinded to the treatment allocation.
Intervention
Patients who fulfilled selection criteria were
randomized 3:1 to the following treatment
groups: pitolisant at 5, 10, or 20 mg once
daily or placebo consumed on an empty
stomach within 1 hour of waking in the
morning. Treatment was initiated at 5 mg by
an individual 2-week titration period,
escalating the dose on the basis of efficacy
and tolerance to the treatment, followed
by treatment with the selected dose for a
further 10 weeks (Figure 1).
Outcomes
The primary efficacy endpoint was the
change from baseline to Week 12 in the ESS
score, a reliable patient self-assessment
method to measure EDS. The key secondary
endpoint was the change from baseline to
Week 12 in the Oxford Sleep Resistance
(OSLER) test, a test of behavioral
maintenance of wakefulness that objectively
measures the ability to maintain
wakefulness. The OSLER test consisted of
three sessions each of 40-minute sleep
resistance challenges performed at 9:00 A.M.,
11:00 A.M., and 1:00 P.M. The mean sleep
latency (mean of the three tests) and the
number of errors (three to six consecutive
errors indicating microsleep and seven or
more errors indicating sleep onset) were
calculated (17, 18). Other secondary
endpoints were responders according to the
ESS (ESS score, <10 or improvement >3
points), Pichot fatigue scale, sleep diary
(sleepiness and sleep episodes), Trail
Making Test parts A and B, Clinical Global
Impression (CGI) severity and change
scales, patient’s global opinion (PGO),
Leeds Sleep Evaluation Questionnaire
(LSEQ), and EuroQol quality-of-life
questionnaire (EQ-5D). Safety was assessed
by evaluating adverse events (particularly
treatment-emergent adverse events
[TEAEs]), clinical laboratory parameters
(hematology, biochemistry, and
electrolytes), vital signs, physical
examination, ECG data, BDI-13 score,
amphetamine-like withdrawal symptoms,
and the patient’s overall evaluation of
tolerance.
Statistical Analysis
Sample size calculation. Results of
exploratory studies on pitolisant provided
an estimate of ESS score residual variability
with an SD of 6 points. The minimal
clinically important difference was
arbitrarily fixed by agreement between the
investigators at ESS score –3, corresponding
to an effect size of 0.5. Recent independent
studies (19, 20) have established the
minimal clinically important improvement
of the ESS score to lie between 22 and 23.
The correlation between final and baseline
ESS scores was conservatively estimated as
r= 0.4. Assuming an analysis of covariance
with a 0.95 confidence level as the main
confirmatory test, a difference of at least 3
points should be detected with a power of
90% by including at least 60 patients in the
placebo group and 180 patients in the
pitolisant treatment group.
Description of the different populations
analyzed. The intention-to-treat (ITT)
population included all randomized
patients. The safety population
corresponded to all patients who received
at least one dose of study medication,
regardless of the outcome, and for whom at
least one valid postbaseline evaluation
(including any adverse event) was available.
The per-protocol population included all
patients in the ITT population with no
major protocol violation regarding inclusion
or noninclusion criteria or during the
treatment phase and no premature
discontinuation in the double-blind phase of
the study. The per-protocol population was
confirmed by blinded review of the data
before database lock.
Demographic data and other baseline
characteristics were analyzed for the ITT
population. The efficacy analysis of the ITT
population was considered as the primary
analysis. The safety population was used for
safety, concomitant medications, exposure,
dosing, and compliance analyses.
The statistical analysis was performed
by an independent external statistician.
Another third-party statistician
independently reviewed the statistical
analysis report. Descriptive statistics were
used for the quantitative variables, and the
frequency distribution was used for the
ordinal and nominal variables. Exact 95%
confidence intervals (CIs) are given for
selected variables.
The final ESS score was compared
between the two arms using a linear mixed
effects model, considering treatment as a
fixed factor, center as a random factor, and
ESS score and BMI at baseline as adjustment
covariates. It was foreseen that the ESS score
might be logarithmically transformed,
depending on normality of the residuals.
However, it appeared that this was not
necessary.
The analysis of safety data was
descriptive, except for between-group
comparisons of the frequencies of TEAEs by
means of logistic regression. Missing data
for the primary efficacy variable and for
response were allocated using the last
observation carried forward (LOCF)
method. An additional sensitivity analysis
was performed in which missing data were
allocated using multiple imputation (see
additional analysis and Tables E1 and E2 in
the online supplement). A sensitivity
analysis for the primary efficacy variable
was performed using the baseline ESS value
carried forward, adjusting for ESS score and
BMI at baseline.
The statistical analysis took into
account the possibility of imbalance between
centers and treatment by considering a
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random factor for centers. All statistical
tests were two sided at a 5% level of
significance.
Results
Patient Flow
Two hundred ninety-eight patients were
screened for inclusion (Figure 2). Of these,
268 patients (89.9%) were eligible for entry
into the double-blind phase of the study
and were randomized to pitolisant (n= 201)
or placebo (n= 67). Among patients in this
ITT population, 267 received at least one
dose of study medication and had a
validated postbaseline assessment,
comprising 200 in the pitolisant group and
67 in the placebo group. These patients
constituted the safety population. Twelve
patients in the ITT population had at least
one major protocol deviation (Table E3),
and 14 patients discontinued the study
prematurely. These 26 patients were
excluded from the per-protocol analysis
that included 181 in the pitolisant group
and 61 in the placebo group.
The ITT population was primarily
male (75.4%) and obese, and the mean
age was 52.0 years. On average, the time
since diagnosis of OSA was 11.9 months;
AHI at diagnosis was 49.3 events per hour;
nocturnal SaO2 was 90.1%; and Mini
Mental State Examination score was
29.4. No significant differences in
demographic or clinical characteristics
were found between the treatment
groups (Table 1).
Primary Efficacy Endpoint
The primary endpoint, change in ESS score
from baseline to end of intervention (LOCF
for ESS), was 26.3 in the pitolisant group
and 23.6 in the placebo group (P, 0.001).
For the mean LOCF for the final ESS score,
the 95% CI for pitolisant (8.8–10.1) versus
placebo (10.7–13.5) did not overlap. The
primary analysis showed a significant
difference in effect between arms of 22.8
(95% CI, 24.0 to 21.5; P, 0.001)
(Figure 3 and Table 2). When missing data
were allocated using multiple imputation,
the multiple imputation analysis confirmed
the LOCF analysis (see Tables E1 and E2).
This was due to the small number of
missing values in this study, which was only
3.0% of the final ESS dataset. Predefined
sensitivity analyses (baseline observation
carried forward) adjusted for BMI and ESS
at baseline showed the same significant
treatment effects.
Secondary Efficacy Outcomes
Pitolisant normalized the ESS score (ESS,
<10) in 67.2% of patients in the study arm
versus 44.8% in the placebo group. An “ESS
response,” defined as either an ESS score
<10 or improvement by 3 or more points,
was observed in 80.6% in the pitolisant
group and 53.7% in the placebo group
(P, 0.001) (Table 2).
The baseline mean sleep latencies
during OSLER tests were 14.796 10.95
minutes and 15.926 11.04 minutes for the
pitolisant and placebo groups, respectively.
The percentages of patients exhibiting the
maximum of 40 minutes were 5.5% and 6%,
whereas those in the 30–40-minute range
were 6.5% and 4.5%, in the pitolisant and
placebo groups, respectively.
The ratios of increase in mean sleep
latency during OSLER tests were 1.65 and
1.39 in the pitolisant and placebo groups,
respectively (P= 0.108 using a mixed
model). The analysis of the mean difference
of the logarithms of sleep latencies between
pitolisant and placebo showed an estimate
of 0.1 (95% CI, 20.0 to 0.3), not reaching
significance. The numbers and types of
errors did not differ between the treatment
groups (Table 3). Similar results were found
in the per-protocol analysis.
There were trends in improvement
in sleep diary variables in the pitolisant
group compared with the placebo group
(number and duration of sleep and
sleepiness episodes; P= 0.056 and P= 0.066,
respectively). Significance was achieved
for these variables in per-protocol
analysis (number and duration of sleep and
sleepiness episodes; P= 0.049 and P= 0.05,
respectively).
Visit 1
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Placebo
Placebo
Placebo
Placebo Placebo Placebo
Pitolisant
Pitolisant
Pitolisant Pitolisant
20 mg
10 mg
5 mg
Pitolisant
20 mg
10 mg
5 mg
20 mg
10 mg10 mg
5 mg5 mg
Placebo
Visit 2
D0
Visit 3
D14
Visit 4
D21
Visit 5
D49
Visit 6
D84
Visit 7
D91
TC 1
D–7
Figure 1. Study design. D=day; DB=double-blind; ESS=Epworth Sleepiness Scale; SB= single blind; TC= telephone call; WO=wash out.
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Major Protocol Violations (N = 9)
Non-Eligible (N = 30)
Total Analysis Set
(Patients Screened)
N = 298
Visit 1 (D–14)
ITT Population
N = 268
SAF Population
N = 267
Visit 3 (D14)
Visit 4 (D21)
Visit 5 (D49)
Visit 6 (D84)
End of DB
Visit 7 (D91)
End of Study
Visit 7 (D91)
End of Study
Discontinued (N = 1)
AE: 1,401
Discontinued (N = 1)
PD: 4,233
Major Protocol Violations (N = 3)
Did not continue in OL (N = 10)
Continued to OL
Pitolisant Treatment Group
N=201
Placebo Group
N=67
N = 66
N = 66
N = 66
N = 65
N = 55 N = 9
N = 199
N = 196
N = 194
N = 190
N = 181N = 9
PP Population
N = 242 61181
Discontinued (N = 1)
PD: 4,508
Discontinued (N = 1)
PD: 4,003 (before treatment)
Discontinued (N = 1)
PD: 4,409
Discontinued (N = 3)
AE: 1,101, 4,213 PD: 4,414
Discontinued (N = 2)
PD: 4,229 LF: 4,905
Discontinued (N = 4)
AE: 5,324 PD: 4,211, 4,413
LF: 3,803
Did not continue in OL (N = 9)
Visit 2 (D0)
Figure 2. Study flowchart. Causes of noneligibility were as follows: 10 due to patient decision and 20 due to exclusion criteria (6 significant cardiovascular
disease or abnormality, 3 Epworth Sleepiness Scale score,12, 2 severe insomnia not associated with obstructive sleep apnea, 2 apnea–hypopnea index
,15 events/h, 2 positive serological test [HIV], 1 severe depression [Beck Depression Inventory score .16], 1 substance abuse [opioids], 1 significant
periodic limb movement disorder and central sleep apnea, 1 age ,18 yr, and 1 adhering to continuous positive airway pressure therapy). AE= adverse
event; D=day; DB=double-blind; ITT= intention to treat; LF= lost to follow-up; OL=open label; PD=patient decision; PP=per protocol; SAF= safety.
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The EQ-5D visual analogue scale
showed average increases of 7.3 mm in the
pitolisant group and 1.8 mm in the placebo
group (P= 0.059). No between-group
differences were found regarding the items
in the LSEQ, except for behavior after
waking with pitolisant (P= 0.018). No
changes were found for the mean time to
perform Trail Making Test part A or B. At
the end of the double-blind phase, 84.2%
of patients in the pitolisant group had
improved their CGI severity and change
scale scores (11.1% very much improved,
44.2% much improved, and 28.9%
minimally improved) compared with 56.3%
in the placebo group (4.7% very much
improved, 29.7% much improved, and
21.9% minimally improved) (P, 0.001).
Improvement in the PGO was expressed by
86.3% of patients in the pitolisant group
(marked effect, 30.0%; moderate effect,
33.7%; minimal effect, 22.6%) compared
with 60.9% in the placebo group (marked
effect, 21.9%; moderate effect, 18.8%;
minimal effect, 20.3%) (P, 0.001). The
mean Pichot fatigue scale scores decreased
from 13.06 6.5 at baseline to 9.26 6.6 at
12 weeks in the pitolisant group and from
11.16 5.9 to 10.56 6.1 in the placebo
group, with a significant mean change
between groups (23.66 5.6 vs. 21.06 6.3;
P= 0.005) (Table 3). During the double-
blind phase, the maximum dose prescribed
was 20 mg/d for 82.5% of patients in the
pitolisant group and for 86.6% of the
patients in the placebo group.
Safety
The safety evaluation was based on the
incidence of TEAEs. No differences were
found for TEAE frequency between the
pitolisant (29.5%) and placebo groups
(25.4%). The most frequently reported
TEAE was headache (8.5% and 11.9% in the
pitolisant and placebo groups, respectively).
Other frequent TEAEs were insomnia,
nausea, and vertigo, reported in 5.5%, 2.5%,
and 2.0% with pitolisant, respectively, and
in 3.0%, 1.5%, and 2.0% with placebo,
respectively (Table 4). Moreover, the
frequency of TEAEs that were considered
treatment related was similar (24.0% with
pitolisant and 19.4% with placebo;
P= 0.377).
TEAEs leading to study drug
withdrawal were reported for three patients
(1.5%) in the pitolisant group and two
patients (3.0%) in the placebo group. Serious
TEAEs were reported for two patients (1.0%;
one prolonged QT interval on the ECG and
one cardiopulmonary failure leading to
death) during pitolisant treatment and
considered unlikely to be treatment related
and in none of the patients receiving
placebo.
The occurrence of amphetamine-like
withdrawal syndrome (dysphoria, defined as
at least three of the following symptoms:
fatigue, vivid and unpleasant dreams,
insomnia or hypersomnia, increased
appetite, and psychomotor retardation
and/or agitation [21]) was assessed in all
participants. None of the patients
experienced amphetamine-like withdrawal
syndrome, and specifically neither
hypersomnia nor fatigue rebound, at
treatment interruption at the end of the
study. All features and symptoms of
withdrawal syndrome are reported in
Table E4. BDI scores, blood chemistry,
Table 1. Demography and Characteristics at Baseline
Parameter Pitolisant (n= 201) Placebo (n=67) All Patients (N=268)
Age, yr, mean (SD) (range) 51.9 (10.6) (25–75) 52.1 (11.0) (30–76) 52.0 (10.6) (25–76)
Sex, n (%)
M 151 (75.1) 51 (76.1) 202 (75.4)
F 50 (24.9) 16 (23.9) 66 (24.6)
Weight at inclusion, kg, mean (SD) 97.7 (15.7) 99.8 (16.1) —
BMI, kg/m2, mean (SD) 32.8 (4.6) 33.0 (4.3) —
Cardiovascular disease, n (%) 110 (54.7) 35 (52.2) 145 (54.1)
AHI at date of diagnosis, events/h, mean (SD) 50.2 (44.3) 46.9 (22.8) 49.3 (40.0)
Nocturnal SaO2 at date of diagnosis, %, mean (SD) 89.8 (9.1) 90.9 (3.8) 90.1 (8.2)
Definition of abbreviations: AHI = apnea–hypopnea index; BMI =body mass index.
–3.74
–5.24
–6.27
–6.63
–3.12
–4.14
–3.76
–3.34
–8
–7
–6
–5
–4
–3
–2
–1
0
0 1 2 3 4 5 6 7 8 9 10 11 12
ES
S 
m
ea
n 
ch
an
ge
 fr
om
 b
as
el
in
e 
(S
E)
Week
pitolisant
placebo
Figure 3. Changes in Epworth Sleepiness Scale (ESS) score during treatment.
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and hematological or cardiovascular
parameters did not change in either group.
During treatment, there were no changes
from baseline in systolic and diastolic blood
pressure or heart rate for both groups
(Table 4). Mean values of the ECG variables
were comparable in the two treatment
groups. However, in the pitolisant
treatment group, three patients (1.5%)
had at least one postdose corrected QT
interval by Fredericia’s corrected QT
interval (QTcF) longer than 450 ms,
and four patients (2.0%) had one QTcF
elongation greater than or equal to 60 ms,
whereas there was one patient with QTcF
longer than 450 ms in the placebo group.
Discussion
Pitolisant reduced self-reported EDS as
measured by the ESS score together with
an overall improvement in both patient-
reported outcomes and physician-assessed
severity in adult patients with OSA with
daytime sleepiness refusing CPAP treatment.
The study population corresponded to
patients with OSA refusing or not tolerating
CPAP treatment. Personalization of sleep
apnea treatment is crucial (22) and is a
prerequisite for optimizing adherence, which
in turn leads to effectiveness. In the case of
CPAP refusal or nonadherence, clinicians
should attempt alternative treatments to
CPAP (23) before offering solely
pharmacologic treatment for sleepiness.
Evidence supports the use of mandibular
advancement devices in mild to moderate
OSAS as providing a health benefit equivalent
to CPAP (24). Maxillomandibular osteotomy
and upper airway stimulation seem to be as
efficient as CPAP in selected young patients
with OSA without comorbidities. Finally,
lifestyle interventions, including weight loss
(25), exercise (26), and/or positional
therapy (27) can be considered as able to at
least reduce OSA severity.
After the dose escalation period, the
mean ESS score was significantly reduced
compared with placebo. The estimate of the
treatment effect based on the change in ESS
score between the beginning and end of the
double-blind intervention was22.8 (95% CI,
24.0 to 21.5). Moreover, the normalization
(ESS score< 10) and responder rates (ESS
score< 10 or improvement >3) were
greater in the group treated with pitolisant.
The magnitude of the change in ESS score
was close to that observed in studies of
modafinil, armodafinil, and solriamfetol in
patients with OSA (10, 11, 28). However,
this should be confirmed by head-to-head
comparisons between wake-promoting
agents. The magnitude of ESS improvement
with pitolisant at Week 12 was substantial
and clinically relevant (19, 20), albeit slightly
weaker than that reported for patients with
narcolepsy treated with pitolisant with doses
often reaching 40 mg (14, 15).
ESS is a patient-reported assessment
of propensity to fall asleep in different
situations of everyday life, whereas the
OSLER test is an objective measure of ability
to maintain wakefulness in a laboratory
environment and the related daytime
vigilance. We found no significant between-
group changes in the OSLER test. However,
the pitolisant group had lower mean sleep
latency at baseline (14.79) than the placebo
group (15.92), and a considerable proportion
of patients exhibited OSLER test mean sleep
latencies in the normal range at baseline (12%
had mean sleep latency >30 min in the
pitolisant group compared with 10% in the
placebo group), and this may have limited
the potential for improvement because of a
ceiling effect.
For several other secondary outcomes
(sleep diaries and EQ-5D), results were
close to statistical significance, becoming
statistically significant in per-protocol
analysis. This suggests that the study might
have been underpowered for some
secondary outcomes. This may also be due
to the inclusion criteria of without CPAP
treatment and with baseline ESS scores>12.
Our population thus differs from the
pivotal trials of modafinil, armodafinil, and
solriamfetol for treatment of EDS in OSA,
in which most of the patients were
receiving CPAP therapy and with an ESS
score >10. Pitolisant was superior to
placebo at the end of the double-blind
phase, with major improvements compared
with placebo in terms of patient-centered
outcomes, including the Pichot fatigue scale
and a feeling of restorative sleep upon
waking (explored by the LSEQ). A clear
improvement was also observed via the
physician-scored (CGI of change) and
patient-scored (PGO) questionnaires.
Adherence to CPAP is a major issue
when treating OSA. It is estimated that
10–15% of patients with OSA initially refuse
or quickly abandon CPAP in the first weeks
of treatment. The long-term rate of CPAP
discontinuation is consistent across studies
at between 20% and 40% (13). No clear
improvement in mean CPAP adherence
has been seen over the last 20 years,
despite considerable technical advances,
behavioral interventions, and multimodal
telemonitoring systems (29, 30). This leaves
Table 2. Efficacy Results for Primary Endpoint: ESS Score
Parameter Pitolisant (n= 201) Placebo (n=67) P Value
ESS score at inclusion, mean (SD) 15.7 (3.1) 15.7 (3.6) —
ESS score at end of treatment, mean (SD) 9.1 (4.7) 12.2 (6.1) —
Final ESS score, DB-LOCF, mean (SD) (95% CI) 9.4 (4.6) (8.8–10.1) 12.1 (5.8) (10.7–13.5) ,0.001
ESS score change, DB-LOCF – V2 26.3 (4.5) 23.6 (5.5) ,0.001
R1 response (ESS score <10)
n (%) 135 (67.2) 30 (44.8) ,0.001
95% CI 60.2–73.6 32.6–57.4
R2 response (ESS score <10 or ESS score
improvement >3)
n (%) 162 (80.6) 36 (53.7) ,0.001
95% CI 74.4–85.8 41.1–66.0
Definition of abbreviations: CI = confidence interval; DB-LOCF=database with last observation carried forward; ESS=Epworth Sleepiness Scale; R1 = first
secondary enpoint result; R2 = second secondary endpoint result; V2= visit 2.
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thousands of patients with symptomatic
OSA with untreated daytime sleepiness. An
original and unique aspect of our study was
the targeted OSA population comprising
only patients with EDS refusing CPAP. In
the two recent solriamfetol studies (11, 28),
the study populations were heterogeneous,
with approximately one-third of patients
having no OSA primary treatment. In the
study by Strollo and colleagues (11), a post
hoc subanalysis showed that ESS score,
maintenance of wakefulness, and CGI
change scale score were slightly better in
nonadherent patients than in those adhering
to CPAP. It remains controversial whether
targeting EDS alone without addressing the
underlying cause is an acceptable practice,
and doing so might lead to misuse. However,
from a pragmatic point of view, these
patients often remain untreated and have a
poor quality of life, loss of productivity, and
risk of EDS-related accidents. Another major
issue beyond symptom improvement is to
ensure that a given wake-promoting agent
Table 3. Efficacy Results for Secondary Outcomes
Parameter Pitolisant (n= 201) Placebo (n= 67) P Value
OSLER test
OSLER test mean sleep latency at inclusion, min, (SD) 14.79 (10.95) 15.92 (11.04) —
Number of patients with OSLER test = 40 min at
inclusion
11 (5.5%) 4 (6%) —
Number of patients with OSLER test >30 min and
,40 min at inclusion
13 (6.5%) 3 (4.5%) —
OSLER test mean sleep latency at end of treatment, min 21.95 (13.53) 20.25 (13.42) —
Ratio of OSLER test V6/OSLER test V2, geometric mean 1.65 1.39 0.120
Mean difference of pitolisant and placebo logarithms of
sleep latency at end of DB treatment (95% CI)
0.1 (0.0–0.3) —
Normal vigilance (number of 3–6 and>7 errors = 0 for each
of the three tests)
At baseline (V2) 2.0% (0.5–5.0%) 3.0% (0.4–10.4%) —
At the end of DB treatment (V6) 8.5% (4.9–13.5%) 6.3% (1.7–15.2%) 0.487
Pichot fatigue score, mean change (SD) 23.6 (5.6) 21.0 (6.3) 0.005
Sleep diary variables
Mean change in daily number of sleep/sleepiness
episodes (SD)
21.79 (1.97) 21.30 (1.86) 0.056*
Mean change in daily duration of sleep/sleepiness
episodes (SD)
247.87 (53.39) 232.24 (48.82) 0.066†
EQ-5D, mean change in VAS score 7.3616.2 1.8616.3 0.059
Leeds Sleep Evaluation Questionnaire
Mean change in modified getting to sleep (SD) 10.21 (24.99) 2.42 (23.51) 0.155
Mean change in quality of sleep (SD) 17.70 (26.08) 13.00 (25.56) 0.108
Mean change in awake after sleep (SD) 19.19 (26.61) 14.00 (25.18) 0.160
Mean change in behavior after awakening (SD) 21.96 (22.26) 13.35 (20.89) 0.018
Mean change in global LSEQ score (SD) 17.26 (14.80) 10.69 (14.80) 0.005
TMT A, mean change in average time (SD) 28.9 (12.7) 27.3 (13.7) 0.389
TMT B, mean change in average time (SD) 222.5 (40.0) 216.3 (33.8) 0.648
CGI ,0.001
Very much improved 21 (11.1%) 3 (4.7%)
Much improved 84 (44.2%) 19 (29.7%)
Minimally improved 55 (28.9%) 14 (21.9%)
No change 30 (15.8%) 22 (34.4%)
Minimally worse 0 (0.0%) 6 (9.4%)
Much worse 0 (0.0%) 0 (0.0%)
Very much worse 0 (0.0%) 0 (0.0%)
CGI improvement at end of DB treatment (V6)
n (%) 160 (84.2%) 36 (56.3%)
95% CI 78.2–89.1% 43.3–68.6%
Patient’s global opinion ,0.001
Improvement at V6, n (%) 164 (86.3%) 39 (60.9%)
95% CI 80.6–90.9% 47.9–72.9%
Definition of abbreviations: CGI =Clinical Global Impression; CI = confidence interval; DB=double-blind; EQ-5D=EuroQol five-dimension quality of life
scale; LSEQ=Leeds Sleep Evaluation Questionnaire; OSLER=Oxford Sleep Resistance test; TMT=Trail Making Test; V2= visit 2; V6= visit 6;
VAS= visual analogue scale.
*P=0.049 in the per-protocol population.
†P=0.050 in the per-protocol population.
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does not precipitate or exacerbate OSA-
related cardiovascular comorbidities, as
already reported for psychostimulants used
in narcolepsy acting via dopamine or
norepinephrine release (31, 32). However, in
this pitolisant trial, no significant changes
were found in terms of blood pressure or
heart rate, which provides a reassurance of
safety. In contrast, in a recent meta-analysis,
modafinil and armodafinil were associated
with a mean increase in systolic blood
pressure of 3.0 mm Hg (95% CI,
0.8–5.2 mm Hg) and a mean increase in
diastolic blood pressure of 1.9 mm Hg (95%
CI, 0.5–3.3 mm Hg) in three of seven trials
(33). In a recent study using solriamfetol, the
highest dose caused increases in systolic and
diastolic blood pressure of 2.5 and
1.5 mm Hg, respectively, and heart rate
increased by 2–3 beats per minute at doses
greater than 75 mg. Again, head-to-head
comparisons of the various clinically
available wake-promoting agents, with
particular focus on cardiovascular outcomes,
are needed.
Our results confirm the favorable safety
profile of pitolisant already reported in
patients with narcolepsy (14, 15). No
key changes were found in physical
examination parameters or vital signs,
depressive symptoms, and ECG or
laboratory test results during the study. The
changes reported in QTc (QTcF, .450 ms
and elongation .60 ms) did not differ
significantly between pitolisant and
placebo. The pitolisant to placebo subject
ratio was 3:1. Hence, there was no
difference in the number of subjects with
post-treatment QTcF values greater than
450 ms (3 of 201 patients [1.5%] in the
pitolisant treatment group and 1 of 67
patients [1.5%] in the placebo group).
These results are similar to those observed
in the previous clinical cardiovascular safety
study (through QT/QTc) with pitolisant
(40 and 120 mg acute), including 58 healthy
volunteers (males and females), in which
1 (1.7%) of 58 subjects exhibited a postdose
QTcF longer than 450 ms, comparable to
the incidence reported in the placebo
period. Accordingly, results reported with
pitolisant in the previous randomized
controlled trials in patients with narcolepsy
(14, 15) did not show any significant
increase in QTc. A recent 1-year open-label
trial in patients with narcolepsy confirmed
the absence of significant ECG changes,
including in the QTc (4096 25 ms at
baseline and 4166 25 ms after 12 mo) (34).
In line with reports of pitolisant use in
patients with narcolepsy, there were no
withdrawal symptoms after abrupt
discontinuation of the drug in sleepy
patients with OSA (14, 15). The overall
tolerance was good, and the incidence
rates of global as well as treatment-related
TEAEs or TEAEs leading to study
withdrawal were similar in both treatment
groups, with no major safety concerns
raised during the study. The most
frequently reported TEAE was headache at
a frequency of 8.5% with pitolisant and
11.9% with placebo, followed by insomnia,
nausea, and vertigo.
The main limitation of this study was its
12-week duration. Long-term maintenance
of efficacy and safety are being evaluated in
an extension of the study. For most patients,
the maximum dose of 20 mg was
administered (82.5% in the pitolisant
group and 86.6% in the placebo group);
however, this dose may potentially have
been too low to achieve maximum
efficiency, as suggested by narcolepsy
studies in which the maximum dose could
be as high as 40 mg/d (14, 15). Moreover,
no dose–response assessment was
conducted, because dose assignment was
not randomized, and dose uptitration is
the standard approach in the clinical use
of pitolisant. In conclusion, in this 12-
week, phase 3 clinical trial, pitolisant
reduced self-reported EDS and improved
patient-reported outcomes, confirmed
by the physician’s CGI, in patients with
OSA refusing or not adhering to CPAP
treatment. n
Table 4. Safety Parameters
Parameter
Pitolisant
(n= 200)
Placebo
(n= 67)
P
Value
Any TEAE, n (%) 59 (29.5) 17 (25.4)
Any treatment-related TEAE, n (%) 48 (24.0) 13 (19.4) 0.377
Any serious TEAE, n (%) 2 (1.0) 0 (0.0)
Any TEAEs leading to study drug withdrawal,
n (%)
3 (1.5) 2 (3.0)
Systolic blood pressure (SD)
At baseline (V2) 128.2 (11.6) 127.2 (7.2)
Range 97 to 180 110 to 145
At end of DB treatment (V6) 127.4 (11.4) 128.5 (10.1)
Range 95 to 185 110 to 160
Mean change (SD) 20.7 (11.6) 1.3 (9.3) 0.313
Range 255 to 30 220 to 33
Diastolic blood pressure (SD)
At baseline (V2) 80.1 (6.6) 80.3 (5.1)
Range 57 to 112 60 to 91
At end of DB treatment (V6) 79.8 (6.4) 80.4 (5.2)
Range 60 to 108 64 to 101
Mean change (SD) 20.2 (7.5) 0.2 (5.9) 0.622
Range 242 to 24 224 to 33
Heart rate (SD)
At baseline (V2) 74.2 (10.2) 72.9 (10.2)
Range 50 to 104 57 to 101
At end of DB treatment (V6) 73.5 (9.8) 73.7 (10.8)
Range 46 to 103 48 to 99
Mean change (SD) 20.3 (9.7) 0.3 (8.4) 0.725
Range 224 to 26 224 to 10
BDI* total score
Mean score at baseline (V2) (SD) 4.7 (3.4) 4.4 (3.6)
95% CI 4.3 to 5.2 3.5 to 5.2
Mean score at end of DB treatment (V6) (SD) 3.7 (3.3) 3.5 (3.7)
95% CI 3.2 to 4.2 2.6 to 4.5
Mean change between baseline and end of
DB treatment
21.0 (2.7) 20.9 (3.2) 0.960
95% CI 21.4 to 20.6 21.7 to 20.1
Definition of abbreviations: BDI =Beck Depression Inventory; CI = confidence interval;
DB=double-blind; TEAE= treatment-emergent adverse event; V2= visit 2; V6= visit 6.
*Thirteen items.
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